Current strategies in the management of hypereosinophilic syndrome, including mepolizumab

Schwartz, Lawrence B.; Sheikh, Javed; Singh, Anish

doi:10.1185/03007995.2010.493132

Cited by 15 publications

(8 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Later, interferon-alpha was introduced to reduce total white blood cell counts and eosinophil percentages (Butterfield and Gleich 1994;Schwartz et al 2010). Recently imatinib has been introduced for the treatment of patients with myeloproliferative HES.…”

Section: Discussionmentioning

confidence: 99%

Equine multisystemic eosinophilic epitheliotropic disease: A case report and review of literature

Bosseler

Verryken

Bauwens

et al. 2013

New Zealand Veterinary Journal

View full text Add to dashboard Cite

Multisystemic eosinophilic epitheliotropic disease is rare in horses, and usually chronic. In the current case the horse showed an apparently acute onset with high fever and rapid clinical deterioration. A diagnosis of MEED should be considered in horses presenting with weight loss and skin lesions with or without fever. A final diagnosis is based on histological results of biopsy specimens from affected organs.

show abstract

Section: Discussionmentioning

confidence: 99%

Equine multisystemic eosinophilic epitheliotropic disease: A case report and review of literature

Bosseler

Verryken

Bauwens

et al. 2013

New Zealand Veterinary Journal

View full text Add to dashboard Cite

show abstract

“…Therefore, we conclude that treatment of early stage multiple myeloma with anti-IL-5 blocking reagents is worth a trial in patients. Multiple anti-human IL-5 blocking reagents are under development for the treatment of eosinophilic conditions and initial studies indicate that these biologicals are well tolerated [54] , [55] .…”

Section: Discussionmentioning

confidence: 99%

Eosinophils and Megakaryocytes Support the Early Growth of Murine MOPC315 Myeloma Cells in Their Bone Marrow Niches

et al. 2014

View full text Add to dashboard Cite

Multiple myeloma is a bone marrow plasma cell tumor which is supported by the external growth factors APRIL and IL-6, among others. Recently, we identified eosinophils and megakaryocytes to be functional components of the micro-environmental niches of benign bone marrow plasma cells and to be important local sources of these cytokines. Here, we investigated whether eosinophils and megakaryocytes also support the growth of tumor plasma cells in the MOPC315.BM model for multiple myeloma. As it was shown for benign plasma cells and multiple myeloma cells, IL-6 and APRIL also supported MOPC315.BM cell growth in vitro, IL-5 had no effect. Depletion of eosinophils in vivo by IL-5 blockade led to a reduction of the early myeloma load. Consistent with this, myeloma growth in early stages was retarded in eosinophil-deficient ΔdblGATA-1 mice. Late myeloma stages were unaffected, possibly due to megakaryocytes compensating for the loss of eosinophils, since megakaryocytes were found to be in contact with myeloma cells in vivo and supported myeloma growth in vitro. We conclude that eosinophils and megakaryocytes in the niches for benign bone marrow plasma cells support the growth of malignant plasma cells. Further investigations are required to test whether perturbation of these niches represents a potential strategy for the treatment of multiple myeloma.

show abstract

“…Additional monoclonal antibodies targeting IL-5 (Reslizumab) or the primary producer of IL-5, eosinophils (alemtuzumab) are also under investigation in HES [17]. Reslizumab is a humanized rat IgG4 monoclonal antibody to IL-5 that is currently in trials for the treatment of pediatric eosinophilic esophagitis, asthma and nasal polyps, although reports of rebound eosinophilia may limit its use [18].…”

Section: Cytokine Blocking Antibodiesmentioning

confidence: 99%

“…Reslizumab is a humanized rat IgG4 monoclonal antibody to IL-5 that is currently in trials for the treatment of pediatric eosinophilic esophagitis, asthma and nasal polyps, although reports of rebound eosinophilia may limit its use [18]. Alemtuzumab is a monoclonal antibody targeting the CD52 receptor present on eosinophils and, in case reports, has shown success in the treatment of refractory HES [17, 19], although its approval at this time remains limited to therapy for chronic lymphocytic leukemia. While these studies show promise for the use of anti-IL-5 therapy in these syndromes, further trials are indicated to elucidate the full beneficial effects and adverse events profile.…”

Section: Cytokine Blocking Antibodiesmentioning

confidence: 99%

Biologic modulators in allergic and autoinflammatory diseases

Broderick

Tourangeau

Kavanaugh

et al. 2011

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of review The advent of molecular techniques has resulted in the ability to tailor medications to specific protein targets. This review will emphasize several biological therapies, specifically directed toward cytokine receptors and inhibitors, and their role in the treatment of atopic and autoinflammatory diseases. Recent findings Translational research and the identification of the molecular pathophysiology of diseases have led to more targeted treatment approaches. The biologic modulators, encompassing monoclonal antibodies as cytokine inhibitors, receptor blocking antibodies and new fusion receptors are now being applied to diseases beyond their original application. Summary The expanded use of biological therapies has experienced success in the treatment of numerous disorders, especially in subsets of patients with disease that has been refractory to conventional therapies.

show abstract

Current strategies in the management of hypereosinophilic syndrome, including mepolizumab

Abstract: Targeted eosinophil-directed therapy with an anti-IL-5 neutralizing monoclonal antibody reduced the need for corticosteroids in these three HES patients without disease exacerbations.

Cited by 15 publications

References 90 publications

Equine multisystemic eosinophilic epitheliotropic disease: A case report and review of literature

Equine multisystemic eosinophilic epitheliotropic disease: A case report and review of literature

Eosinophils and Megakaryocytes Support the Early Growth of Murine MOPC315 Myeloma Cells in Their Bone Marrow Niches

Biologic modulators in allergic and autoinflammatory diseases

Contact Info

Product

Resources

About